{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T10:44:08Z","timestamp":1791974648872,"version":"4.4.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Hollings Cancer Center Abney Fellowship"},{"name":"National Cancer Institute","award":["P30 CA138313"],"award-info":[{"award-number":["P30 CA138313"]}]},{"name":"National Cancer Institute","award":["P30 CA138313"],"award-info":[{"award-number":["P30 CA138313"]}]},{"name":"National Cancer Institute","award":["P30 CA138313"],"award-info":[{"award-number":["P30 CA138313"]}]},{"name":"National Cancer Institute","award":["P30 CA138313"],"award-info":[{"award-number":["P30 CA138313"]}]},{"DOI":"10.13039\/100000090","name":"Congressionally Directed Medical Research Programs","doi-asserted-by":"crossref","award":["W81XWH-18-1-0007"],"award-info":[{"award-number":["W81XWH-18-1-0007"]}],"id":[{"id":"10.13039\/100000090","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000090","name":"Congressionally Directed Medical Research Programs","doi-asserted-by":"crossref","award":["W81XWH-18-1-0007"],"award-info":[{"award-number":["W81XWH-18-1-0007"]}],"id":[{"id":"10.13039\/100000090","id-type":"DOI","asserted-by":"crossref"}]},{"name":"South Carolina SmartState\u2122 Program"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"DOI":"10.1186\/s13058-025-02176-6","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T23:01:52Z","timestamp":1764889312000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Secreted frizzled-related protein 2 monoclonal antibody-mediated IFN-\u03d2 reprograms tumor-associated macrophages to suppress triple negative breast cancer"],"prefix":"10.1186","volume":"27","author":[{"given":"Lillian","family":"Hsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Siegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Nasarre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel","family":"Oberholtzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupak","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor","family":"Hilliard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paramita","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel A.","family":"Burge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth C.","family":"O\u2019Quinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Sweatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Faisal","family":"Kassir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Aaron","family":"Hobbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ostrowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Marie","family":"Broome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shikhar","family":"Mehrotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Klauber-DeMore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"key":"2176_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13153739","author":"F Hossain","year":"2021","unstructured":"Hossain F, Majumder S, David J, Miele L. Precision medicine and triple-negative breast cancer: current landscape and future directions. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13153739.","journal-title":"Cancers (Basel)"},{"key":"2176_CR2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-3402","author":"A Courtwright","year":"2009","unstructured":"Courtwright A, Siamakpour-Reihani S, Arbiser JL, Banet N, Hilliard E, Fried L, et al. Secreted frizzle-related protein 2 stimulates angiogenesis via a calcineurin\/NFAT signaling pathway. Cancer Res. 2009. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-3402.","journal-title":"Cancer Res"},{"issue":"4","key":"2176_CR3","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s10456-017-9574-5","volume":"20","author":"YK Peterson","year":"2017","unstructured":"Peterson YK, Nasarre P, Bonilla IV, Hilliard E, Samples J, Morinelli TA, et al. Frizzled-5: a high affinity receptor for secreted frizzled-related protein-2 activation of nuclear factor of activated T-cells c3 signaling to promote angiogenesis. Angiogenesis. 2017;20(4):615\u201328.","journal-title":"Angiogenesis"},{"issue":"6","key":"2176_CR4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0020412","volume":"6","author":"S Siamakpour-Reihani","year":"2011","unstructured":"Siamakpour-Reihani S, Caster J, Bandhu ND, Courtwright A, Hilliard E, Usary J, et al. The role of calcineurin\/NFAT in SFRP2 induced angiogenesis-a rationale for breast cancer treatment with the calcineurin inhibitor tacrolimus. PLoS ONE. 2011;6(6):e20412.","journal-title":"PLoS ONE"},{"issue":"3","key":"2176_CR5","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41556-020-0474-3","volume":"22","author":"M Montagner","year":"2020","unstructured":"Montagner M, Bhome R, Hooper S, Chakravarty P, Qin X, Sufi J, et al. Crosstalk with lung epithelial cells regulates Sfrp2-mediated latency in breast cancer dissemination. Nat Cell Biol. 2020;22(3):289\u201396.","journal-title":"Nat Cell Biol"},{"key":"2176_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13112696","author":"P Nasarre","year":"2021","unstructured":"Nasarre P, Garcia DI, Siegel JB, Bonilla IV, Mukherjee R, Hilliard E, et al. Overcoming PD-1 inhibitor resistance with a monoclonal antibody to secreted frizzled-related protein 2 in metastatic osteosarcoma. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13112696.","journal-title":"Cancers (Basel)"},{"issue":"9","key":"2176_CR7","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1158\/2159-8290.CD-17-1033","volume":"8","author":"L Chen","year":"2018","unstructured":"Chen L, Diao L, Yang Y, Yi X, Rodriguez BL, Li Y, et al. CD38-Mediated immunosuppression as a mechanism of tumor cell escape from PD-1\/PD-L1 blockade. Cancer Discov. 2018;8(9):1156\u201375.","journal-title":"Cancer Discov"},{"issue":"5","key":"2176_CR8","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.2353\/ajpath.2008.070988","volume":"172","author":"R Bhati","year":"2008","unstructured":"Bhati R, Patterson C, Livasy CA, Fan C, Ketelsen D, Hu Z, et al. Molecular characterization of human breast tumor vascular cells. Am J Pathol. 2008;172(5):1381\u201390. https:\/\/doi.org\/10.2353\/ajpath.2008.070988.","journal-title":"Am J Pathol"},{"key":"2176_CR9","doi-asserted-by":"publisher","DOI":"10.1177\/0963689720962479","volume":"29","author":"ZH Wu","year":"2020","unstructured":"Wu ZH, Zhang YJ, Yue JX, Zhou T. Comprehensive analysis of the expression and prognosis for SFRPs in breast carcinoma. Cell Transplant. 2020;29:963689720962479.","journal-title":"Cell Transplant"},{"key":"2176_CR10","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/6149381","volume":"2019","author":"C Huang","year":"2019","unstructured":"Huang C, Ye Z, Wan J, Liang J, Liu M, Xu X, et al. Secreted frizzled-related protein 2 is associated with disease progression and poor prognosis in breast cancer. Dis Markers. 2019;2019:6149381. https:\/\/doi.org\/10.1155\/2019\/6149381.","journal-title":"Dis Markers"},{"issue":"13","key":"2176_CR11","doi-asserted-by":"publisher","first-page":"4782","DOI":"10.1245\/s10434-019-07800-2","volume":"26","author":"D Garcia","year":"2019","unstructured":"Garcia D, Nasarre P, Bonilla IV, Hilliard E, Peterson YK, Spruill L, et al. Development of a novel humanized monoclonal antibody to secreted frizzled-related protein-2 that inhibits triple-negative breast cancer and angiosarcoma growth in vivo. Ann Surg Oncol. 2019;26(13):4782\u201390. https:\/\/doi.org\/10.1245\/s10434-019-07800-2.","journal-title":"Ann Surg Oncol"},{"issue":"15 Pt 1","key":"2176_CR12","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","volume":"13","author":"R Dent","year":"2007","unstructured":"Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15 Pt 1):4429\u201334. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-3045.","journal-title":"Clin Cancer Res"},{"issue":"6220","key":"2176_CR13","doi-asserted-by":"publisher","DOI":"10.1126\/science.1260419","volume":"347","author":"M Uhlen","year":"2015","unstructured":"Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Tissue-based map of the human proteome. Science. 2015;347(6220):1260419.","journal-title":"Science"},{"issue":"3","key":"2176_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0174281","volume":"12","author":"JK Tsuruta","year":"2017","unstructured":"Tsuruta JK, Schaub NP, Rojas JD, Streeter J, Klauber-DeMore N, Dayton P. Optimizing ultrasound molecular imaging of secreted frizzled related protein 2 expression in angiosarcoma. PLoS ONE. 2017;12(3):e0174281. https:\/\/doi.org\/10.1371\/journal.pone.0174281.","journal-title":"PLoS ONE"},{"issue":"1","key":"2176_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0086642","volume":"9","author":"JK Tsuruta","year":"2014","unstructured":"Tsuruta JK, Klauber-DeMore N, Streeter J, Samples J, Patterson C, Mumper RJ, et al. Ultrasound molecular imaging of secreted frizzled related protein-2 expression in murine angiosarcoma. PLoS ONE. 2014;9(1):e86642. https:\/\/doi.org\/10.1371\/journal.pone.0086642.","journal-title":"PLoS ONE"},{"key":"2176_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.597959","volume":"11","author":"ZL Piedra-Quintero","year":"2020","unstructured":"Piedra-Quintero ZL, Wilson Z, Nava P, Guerau-de-Arellano M. CD38: an immunomodulatory molecule in inflammation and autoimmunity. Front Immunol. 2020;11:597959. https:\/\/doi.org\/10.3389\/fimmu.2020.597959.","journal-title":"Front Immunol"},{"key":"2176_CR17","unstructured":"The Human Protein Atlas [https:\/\/www.proteinatlas.org\/ENSG00000145423-SFRP2\/single+cell#expression_cluster. Available from: Human Protein Atlas proteinatlas.org."},{"key":"2176_CR18","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s40364-020-00228-x","volume":"8","author":"D Jorgovanovic","year":"2020","unstructured":"Jorgovanovic D, Song M, Wang L, Zhang Y. Roles of IFN-gamma in tumor progression and regression: a review. Biomark Res. 2020;8:49.","journal-title":"Biomark Res"},{"issue":"1","key":"2176_CR19","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13058-015-0621-0","volume":"17","author":"S Sousa","year":"2015","unstructured":"Sousa S, Brion R, Lintunen M, Kronqvist P, Sandholm J, Monkkonen J, et al. Human breast cancer cells educate macrophages toward the M2 activation status. Breast Cancer Res. 2015;17(1):101.","journal-title":"Breast Cancer Res"},{"issue":"1","key":"2176_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00522-z","volume":"8","author":"S Wang","year":"2024","unstructured":"Wang S, Wang J, Chen Z, Luo J, Guo W, Sun L, et al. Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance. NPJ Precis Oncol. 2024;8(1):31. https:\/\/doi.org\/10.1038\/s41698-024-00522-z.","journal-title":"NPJ Precis Oncol"},{"issue":"21","key":"2176_CR21","doi-asserted-by":"publisher","first-page":"5709","DOI":"10.1158\/1078-0432.CCR-20-0446","volume":"26","author":"ME Fane","year":"2020","unstructured":"Fane ME, Ecker BL, Kaur A, Marino GE, Alicea GM, Douglass SM, et al. SFRP2 supersedes VEGF as an age-related driver of angiogenesis in melanoma, affecting response to anti-VEGF therapy in older patients. Clin Cancer Res. 2020;26(21):5709\u201319. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-0446.","journal-title":"Clin Cancer Res"},{"key":"2176_CR22","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-12-1066","author":"E Fontenot","year":"2013","unstructured":"Fontenot E, Rossi E, Mumper R, Snyder S, Siamakpour-Reihani S, Ma P, et al. A novel monoclonal antibody to secreted frizzled related protein 2 inhibits tumor growth. Mol Cancer Ther. 2013. https:\/\/doi.org\/10.1158\/1535-7163.MCT-12-1066.","journal-title":"Mol Cancer Ther"},{"key":"2176_CR23","doi-asserted-by":"publisher","first-page":"1370800","DOI":"10.3389\/fimmu.2024.1370800","volume":"15","author":"S Zhi","year":"2024","unstructured":"Zhi S, Chen C, Huang H, Zhang Z, Zeng F, Zhang S. Hypoxia-inducible factor in breast cancer: role and target for breast cancer treatment. Front Immunol. 2024;15:1370800.","journal-title":"Front Immunol"},{"issue":"11","key":"2176_CR24","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1038\/sj.onc.1204235","volume":"20","author":"NJ Turton","year":"2001","unstructured":"Turton NJ, Judah DJ, Riley J, Davies R, Lipson D, Styles JA, et al. Gene expression and amplification in breast carcinoma cells with intrinsic and acquired doxorubicin resistance. Oncogene. 2001;20(11):1300\u20136.","journal-title":"Oncogene"},{"issue":"1","key":"2176_CR25","doi-asserted-by":"publisher","DOI":"10.4161\/onci.22339","volume":"2","author":"CY Slaney","year":"2013","unstructured":"Slaney CY, Moller A, Hertzog PJ, Parker BS. The role of Type I interferons in immunoregulation of breast cancer metastasis to the bone. Oncoimmunology. 2013;2(1):e22339. https:\/\/doi.org\/10.4161\/onci.22339.","journal-title":"Oncoimmunology"},{"key":"2176_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10051130","author":"H Kim","year":"2022","unstructured":"Kim H, Choi JM, Lee KM. Immune checkpoint blockades in triple-negative breast cancer: current state and molecular mechanisms of resistance. Biomedicines. 2022. https:\/\/doi.org\/10.3390\/biomedicines10051130.","journal-title":"Biomedicines"},{"issue":"3","key":"2176_CR27","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.it.2020.01.008","volume":"41","author":"P Chakraborty","year":"2020","unstructured":"Chakraborty P, Mehrotra S. CD38: modulating histone methyltransferase EZH2 activity in SLE. Trends Immunol. 2020;41(3):187\u20139.","journal-title":"Trends Immunol"},{"issue":"1","key":"2176_CR28","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cmet.2017.10.006","volume":"27","author":"S Chatterjee","year":"2018","unstructured":"Chatterjee S, Daenthanasanmak A, Chakraborty P, Wyatt MW, Dhar P, Selvam SP, et al. CD38-NAD(+)axis regulates immunotherapeutic anti-tumor T cell response. Cell Metab. 2018;27(1):85-100 e8.","journal-title":"Cell Metab"},{"issue":"1","key":"2176_CR29","first-page":"60","volume":"65","author":"LJ Richter","year":"2020","unstructured":"Richter LJ. PRACTITIONER APPLICATION: quality, costs, and policy: factors influencing choice of anesthesia staffing models. J Healthc Manag. 2020;65(1):60\u20131.","journal-title":"J Healthc Manag"},{"key":"2176_CR30","unstructured":"INNOVA THERAPEUTICS: Receives rare pediatric disease designation from the food and drug administration (FDA) for IVT-8086 for the treatment of osteosarcoma 2021 [Available from: https:\/\/fdahealthnews.com\/stories\/555555018-innova-therapeutics-receives-rare-pediatric-disease-designation-from-the-food-and-drug-administration-fda-for-ivt-8086-for-the-treatment-of-osteosarcoma."},{"issue":"1","key":"2176_CR31","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1186\/s12885-016-2909-6","volume":"16","author":"P Techavichit","year":"2016","unstructured":"Techavichit P, Gao Y, Kurenbekova L, Shuck R, Donehower LA, Yustein JT. Secreted frizzled-related protein 2 (sFRP2) promotes osteosarcoma invasion and metastatic potential. BMC Cancer. 2016;16(1):869.","journal-title":"BMC Cancer"},{"key":"2176_CR32","unstructured":"Gene Expression Omnibus [http:\/\/www.ncbi.nlm.nih.gov\/geo\/]."},{"issue":"7598","key":"2176_CR33","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/nature17392","volume":"532","author":"A Kaur","year":"2016","unstructured":"Kaur A, Webster MR, Marchbank K, Behera R, Ndoye A, Kugel CH 3rd, et al. sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. Nature. 2016;532(7598):250\u20134.","journal-title":"Nature"},{"issue":"6","key":"2176_CR34","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1158\/1535-7163.MCT-10-0012","volume":"9","author":"S Yamamura","year":"2010","unstructured":"Yamamura S, Kawakami K, Hirata H, Ueno K, Saini S, Majid S, et al. Oncogenic functions of secreted Frizzled-related protein 2 in human renal cancer. Mol Cancer Ther. 2010;9(6):1680\u20137. https:\/\/doi.org\/10.1158\/1535-7163.MCT-10-0012.","journal-title":"Mol Cancer Ther"},{"key":"2176_CR35","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000002328","author":"H Liu","year":"2023","unstructured":"Liu H, Zhou L, Cheng H, Wang S, Luan W, Cai E, et al. Characterization of candidate factors associated with the metastasis and progression of high-grade serous ovarian cancer. Chin Med J (Engl). 2023. https:\/\/doi.org\/10.1097\/CM9.0000000000002328.","journal-title":"Chin Med J (Engl)"},{"issue":"1","key":"2176_CR36","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/s13046-022-02425-y","volume":"41","author":"HK Charles Jacob","year":"2022","unstructured":"Charles Jacob HK, Signorelli R, Charles Richard JL, Kashuv T, Lavania S, Middleton A, et al. Identification of novel early pancreatic cancer biomarkers KIF5B and SFRP2 from \u201cfirst contact\u201d interactions in the tumor microenvironment. J Exp Clin Cancer Res. 2022;41(1):258.","journal-title":"J Exp Clin Cancer Res"},{"key":"2176_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/life11060522","author":"D Liu","year":"2021","unstructured":"Liu D, Sun C, Kim N, Bhan C, Tuason JPW, Chen Y, et al. Comprehensive analysis of SFRP family members prognostic value and immune infiltration in gastric cancer. Life (Basel). 2021. https:\/\/doi.org\/10.3390\/life11060522.","journal-title":"Life (Basel)"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-025-02176-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-025-02176-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-025-02176-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T23:01:54Z","timestamp":1764889314000},"score":1,"resource":{"primary":{"URL":"https:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/s13058-025-02176-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2176"],"URL":"https:\/\/doi.org\/10.1186\/s13058-025-02176-6","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]},"assertion":[{"value":"3 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"IRB exemption was obtained to use four de-identified FFPE human TNBCs from the MUSC Biorepository and Tissue Analyses Shared Resource. All animal studies were reviewed and approved by the Institutional Animal Care and Use Committee at MUSC and conducted in accordance with the National Institutes of Health guide for the care and use of laboratory animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"A Humanized Monoclonal Antibody to SFRP2 for Tumor-Associated Macrophage Reduction and Polarization in Cancer, Patent application # 63\/568,165, Nancy Klauber-DeMore, Lillian Hsu, Patrick Nasarre, March 21, 2024. Discovery of Novel Targets for Angiogenesis Inhibition, Patent application # 61\/053397, Inventor: Nancy Klauber-DeMore, MD. Pharmaceutical Combination for the Treatment of Cancer, Provisional patent # 112746-99263, Inventor: Nancy Klauber-DeMore, MD. Compositions and Methods Comprising SFRP2 Antagonists, Patent application # PCT\/US2021\/062854, Inventor: Nancy Klauber-DeMore, MD. Dr. Nancy Klauber-DeMore is a co-founder of Enci Therapeutics, Inc. and co-founder of Innova Therapeutics, Inc. The remaining authors declare no disclosures.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"209"}}